Peggy Scherle, Chief Scientific Officer at Prelude Therapeutics Inc (PRLD), sold 30,540 shares at $39.02 ($1.2M) on 2021-04-07, disclosed to the SEC on 2021-04-09.
Open-market sale of $1.2M PRLD by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.02 | 8,289 | $323K | 26.9% |
| 2 | $39.02 | 8,289 | $323K | 26.9% |
| 3 | $39.63 | 6,881 | $273K | 22.7% |
| 4 | $39.63 | 6,881 | $273K | 22.7% |
| 5 | $40.30 | 200 | $8K | 0.7% |
| Total | $39.30 avg | 30,540 |
| $1.2M |
| 100% |
| Filing → |
| PRLD | SELL | 2021-07-29 | $709K | — | Filing → |
| PRLD | SELL | 2021-05-11 | $808K | — | Filing → |
| PRLD | SELL | 2021-04-15 | $296K | — | Filing → |